Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 8/20 | 0.36 |
| ▸ | RGS4 | P49798 | 3/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | DAO | P14920 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CCR6 | P51684 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | RGS8 | P57771 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12997397 | 0.89 | RGS4 (0.37) | GRM2RGS4DAORGS8 | |
| SCHEMBL19493726 | 0.83 | RGS4 (0.44) | RGS4LMNACCR6L3MBTL1RGS8 | |
| SCHEMBL15984388 | 0.80 | RGS4 (0.35) | RGS4HTTDAOLMNASMN1; SMN2 | |
| SCHEMBL12997387 | 0.79 | RGS4 (0.33) | RGS4DAO | |
| SCHEMBL16938090 | 0.79 | DAO (0.39) | GRM2RGS4HTTDAO | |
| SCHEMBL19493727 | 0.77 | CYP3A4 (0.50) | L3MBTL1SMN1; SMN2HSD17B10 | |
| SCHEMBL25867919 | 0.75 | RGS4 (0.43) | RGS4RGS8 | |
| SCHEMBL14226996 | 0.75 | CYP3A4 (0.57) | L3MBTL1SMN1; SMN2CYP1A2 | |
| SCHEMBL13223313 | 0.75 | RGS4 (0.52) | RGS4L3MBTL1RGS8CYP1A2CYP2C19 | |
| SCHEMBL22152939 | 0.74 | DAO (0.42) | GRM2RGS4DAORGS8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9023588-B2 | Resist underlayer film forming composition containing silicon having nitrogen-containing ring | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2015-05-05 | — | — | US | disclosed |
| US-20120315765-A1 | RESIST UNDERLAYER FILM FORMING COMPOSITION CONTAINING SILICON HAVING NITROGEN-CONTAINING RING | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2012-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120315765-A1 | RESIST UNDERLAYER FILM FORMING COMPOSITION CONTAINING SILICON HAVING NITROGEN-CONTAINING RING | SRSF1, SRSF7, SRRM2 | GRM2 3256/4885RGS4 2843/4885HTT 4062/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.